Specialty Pharmaceutical Partnering Deals, 2014-2020 - Trends, Deal Structure, Case Studies, Leading Deals by Value, Most Active Dealmakers

DUBLIN, March 16, 2020 /PRNewswire/ -- The "Global Specialty Pharmaceutical Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2020 provides a detailed understanding and analysis of how and why companies enter Specialty Pharmaceutical partnering deals.

• Trends in Specialty Pharmaceutical dealmaking in the biopharma industry since 2014
• Analysis of Specialty Pharmaceutical deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life Specialty Pharmaceutical deals
• Access to Specialty Pharmaceutical contract documents
• Leading Specialty Pharmaceutical deals by value since 2014
• Most active Specialty Pharmaceutical dealmakers since 2014

The report takes the reader through a comprehensive review Specialty Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Specialty Pharmaceutical partnering deals.

The report presents financial deal term values for Specialty Pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Specialty Pharmaceutical partnering field; both the leading deal values and most active Specialty Pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 900 online deal records of actual Specialty Pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Specialty Pharmaceutical dealmaking.

• Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Specialty Pharmaceutical dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Specialty Pharmaceutical deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 25 most active companies in Specialty Pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of Specialty Pharmaceutical deals announded by that company, as well as contract documents, where available.
• Chapter 5 provides a comprehensive and detailed review of Specialty Pharmaceutical partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive and detailed review of Specialty Pharmaceutical partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Specialty Pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Specialty Pharmaceutical partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Specialty Pharmaceutical technologies and products.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

• 5LINX
• 8E6Tong
• 22nd Century
• 48North Cannabis
• Abattis Bioceuticals
• Abba Import Export
• Abbott Laboratories
• Abbvie
• Abic Marketing
• Ability Pharmaceuticals
• AB InBev
• Abiogen Pharma
• Ablynx
• Accelis Pharma
• Acerus
• Aceto Corporation
• Achieve Life Science
• Acnos Pharma
• Acorda Therapeutics
• Acres Cannabis
• Actavis (acquired by Watson)
• Actavis (name changed to Allergan)
• Actavis Foshan
• Acura Pharmaceuticals
• AdAlta
• Adaptive Biotechnologies
• Adapt Pharma
• Adare Pharmaceuticals
• Adcock Ingram
• Addex Therapeutics
• ADL Bionatur Solutions
• ADMA Biologics
• Advanced Accelerator Applications
• Advanced Dosage Forms
• Advanced Extraction Systems
• Advanced Medical Solutions
• Advance Pharmaceutical
• Advanz Pharma
• Advicenne
• Aegis Therapeutics
• Aeon Bioscience
• Aequus Pharmaceuticals
• Aerial BioPharma
• Aerie Pharmaceuticals
• Aesthetic Management Partners
• Aevum Life Science
• AFT Pharmaceuticals
• Agile Therapeutics
• AgMedica Bioscience
• Akkadeas Pharma
• Akorn
• Akums Drugs and Pharmaceuticals
• Albany Molecular Research
• Albion
• Albireo
• Aleafia Health
• Alfasigma
• Algae Dynamics
• Alimentary Health
• Allegis Holdings
• Allegro Ophthalmics
• Allergan
• Alliance Pharma
• AllianceRx Walgreens Prime
• Allied Laboratories
• All Star Health Brands
• Almirall
• Alnylam Pharmaceuticals
• Altan Pharma
• Altus Formulation
• Alvit LCS Pharma
• Alvogen
• Amag Pharmaceuticals
• Amarantus BioSciences
• Amarillo Biosciences
• Amarin
• Ambrosia Nutraceuticals
• Amend Surgical
• American Medical Systems
• AmeriCann
• American Regent
• AmerisourceBergen
• Amherst Pharmaceuticals
• Amneal Pharmaceuticals
• AMO Pharma
• Amphastar Pharmaceuticals
• Ampio Pharmaceuticals
• Amyris
• Anahit
• AnaptysBio
• Andromeda Biotech
• Andrus
• Angelini Pharma
• ANI Pharmaceuticals
• AOP Orphan Pharmaceuticals
• Aperion Biologics
• Aphria
• Apicore
• Apotex
• AppianRx
• Applied DNA Sciences
• APR Applied Pharma Research
• Apricus Biosciences
• Aptuit
• Aqua Pharmaceuticals
• Aquestive Therapeutics
• Aradigm
• Aralez Pharmaceuticals
• AR Brown
• Ardelyx
• Arena Pharmaceuticals
• Ariad Pharmaceuticals
• Aries Pharmaceuticals
• Arjuna Naturals
• ArmaGen
• Armas Pharmaceuticals
• Armetheon
• Army & Air Force Exchange Service
• Asana Biosciences
• Ascendia Pharmaceuticals
• Ascend Therapeutics
• Asceneuron
• Aseptix
• ASKA Pharmaceuticals
• Aspen Global
• Aspen Holding
• Assuta Medical Centers
• Astellas Pharma US
• AstraZeneca
• and many more!

For more information about this report visit https://www.researchandmarkets.com/r/c1of7h

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com